DBP

No serious adverse effects in GLP-tox preliminary study for Temodex

Mon, Oct 16, 2017 08:00 CET

Double Bond Pharmaceutical (DBP) has initiated the toxicological evaluation of the company's drug candidate against brain cancer, Temodex, as announced earlier. This study package is intended to demonstrate the safety of Temodex in the brain in rats to clarify the improved safety profile seen in previous studies. The toxicological package begins with a preliminary study followed by the major GLP study.The first animals have now been dosed in the preliminary study without observing any serious adverse effects."The preliminary results we have obtained are entirely in line with the

The pre-clinical toxicological development of SA-033 is now completed

Tue, Apr 18, 2017 08:00 CET

DBP has now completed the final part of the toxicological studies required to apply for clinical trials of SA-033 – drug candidate against cancers in liver. SA-033 is a novel self-navigating formulation based on the known cancer drug doxorubicin.The final part of the pre-clinical development was comprised of a toxicology study performed in accordance to GLP-standard (i.e. the highest standard) where the ordinary doxorubicin was compared with the SA- 033 formulation. The purpose of this part of the toxicology program was to develop a detailed profile of SA-033 toxicity. The results show

Share

No serious adverse effects in GLP-tox preliminary study for Temodex

The pre-clinical toxicological development of SA-033 is now completed

Subscribe